[HTML][HTML] Oral antiviral treatments for COVID-19: opportunities and challenges
L Rahmah, SO Abarikwu, AG Arero, M Essouma… - Pharmacological …, 2022 - Springer
The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …
and prevent disease progression to a more severe form. However, the timing of antiviral …
Effectiveness of molnupiravir in high-risk patients: a propensity score matched analysis
R Najjar-Debbiny, N Gronich, G Weber… - Clinical infectious …, 2023 - academic.oup.com
Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …
[HTML][HTML] Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial
R Zou, L Peng, D Shu, L Zhao, J Lan, G Tan… - Frontiers in …, 2022 - frontiersin.org
Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has
unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved …
unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved …
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach
R Dal-Ré, SL Becker, E Bottieau… - The Lancet Infectious …, 2022 - thelancet.com
The first two oral antivirals, molnupiravir and nirmatrelvir–ritonavir, are now becoming
available in many countries. These medicines will be indicated to treat mild-to-moderate …
available in many countries. These medicines will be indicated to treat mild-to-moderate …
[HTML][HTML] Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice
Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of
coronavirus disease 2019 (COVID-19), has incited a global health crisis. Currently, there are …
coronavirus disease 2019 (COVID-19), has incited a global health crisis. Currently, there are …
[HTML][HTML] Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus …
Background COVID-19 has overwhelmed health services globally. Oral antiviral therapies
are licensed worldwide, but indications and efficacy rates vary. We aimed to evaluate the …
are licensed worldwide, but indications and efficacy rates vary. We aimed to evaluate the …
[PDF][PDF] Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
Summary The SARS-CoV-2 3CL protease (3CL pro) is an attractive therapeutic target, as it
is essential to the virus and highly conserved among coronaviruses. However, our current …
is essential to the virus and highly conserved among coronaviruses. However, our current …
[HTML][HTML] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2 …
WHK Schilling, P Jittamala, JA Watson… - The Lancet Infectious …, 2024 - thelancet.com
Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …
19 antiviral treatments, but their antiviral activities in patients have not been compared …
Recent drug development and medicinal chemistry approaches for the treatment of SARS‐CoV‐2 infection and COVID‐19
Abstract COVID‐19, caused by SARS‐CoV‐2 infection, continues to be a major public
health crisis around the globe. Development of vaccines and the first cluster of antiviral …
health crisis around the globe. Development of vaccines and the first cluster of antiviral …